Moderna
MRNA | NASDAQ
$215.27
-$8.10 (-3.63%)
At close: Nov 16, 2026, 4:00 PM ET
$213.18
-$2.09 (-0.97%)
After-hours:
Nov 16, 2026, 7:59 PM ET
Moderna Company Profile
Company profile explainedCompany Profile
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Stéphane Bancel | Chief Executive Officer & Director |
| James Mock | Chief Financial Officer |
| Juan Andres | Chief Operating Officer |
| Shannon Thyme Klinger | Chief Legal Officer & Corporate Secretary |
| Charbel Haber | Senior Vice President & Head of Global Regulatory Science |
| Chris Ridley | VP & Global Head of Communications |
| Jerh Collins | Chief Technical Operations & Quality Officer |
| John Lepore | Senior Vice President of Government Engagement |
| Lavina Talukdar | Senior Vice President & Head of Investor Relations |
| Patrick Norman Bergstedt | Senior Vice President of Commercial Vaccines |
| Stephen Hoge | President |
| Tracey Franklin | Chief People & Digital Technology Officer |
Moderna
| Country | United States |
| IPO Date | Dec 7, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4,700 |
| CEO | Stéphane Bancel |
Contact Details
325 Binney Street Cambridge,
Massachusetts 02142 United States
Stock Details
| Ticker Symbol | MRNA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001682852 |
| CUSIP Number | 60770K107 |
| ISIN Number | US60770K1079 |
| SIC Code | 2836 |
Recent News
- 9 hours ago / fool.comIs Moderna's Cancer Vaccine a Game Changer for the Stock?
- 2 days ago / fool.comAxsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?
- 3 days ago / zacks.comModerna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls
- 4 days ago / barrons.comBioNTech May Be the Next Moderna. Even if it Isn't, the Stock Is a Buy.
- 4 days ago / marketbeat.comModerna Targets 2027 Cancer Therapy Launch, Raises 2026 Revenue Growth Outlook
- 4 days ago / zacks.comMRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?
- 4 days ago / fool.comWhy Moderna Stock Dropped on Thursday
- 4 days ago / barrons.comModerna Needs a Post-Covid Hit. Its Cancer-Drug Spending Plan Ups the Stakes.
- 7 days ago / fool.comModerna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy
- 8 days ago / zacks.comCan Moderna's First Cancer Therapy Win FDA Approval in 2027?
Add to Watchlist
Select watchlists to add or remove MRNA